Learn More
Invitrogen™ p21 Monoclonal Antibody (GT1032)

Description
Keep as concentrated solution. Predicted reactivity: Cat (84%), Sheep (82%), Rhesus Monkey (98%), Bovine (83%). Positive Control: HeLa, HCT116 (30 μM Cisplatin treatment for 24 hr), HCT116 (30 μM Cisplatin treatment for 48 hr). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Specifications
Specifications
| Antigen | p21 |
| Applications | Flow Cytometry, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | GT1032 |
| Concentration | 0.8 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with no preservative |
| Gene | CDKN1A |
| Gene Accession No. | P38936, P39689 |
| Gene Alias | Activating Fragment 1; CAP20; cdk inhibitor CIP1; cdk inhibitor CIP1 (p21); CDKI; CDK-interacting protein 1; CDK-interaction protein 1; Cdkn1; CDKN1A; CDNK1A; CIP1; Cip1); cyclin dependent kinase inhibitor 1A; cyclin-dependent kinase inhibitor 1; cyclin-dependent kinase inhibitor 1A; Cyclin-dependent kinase inhibitor 1A (p21; cyclin-dependent kinase inhibitor 1A (P21); cyclin-dependent kinase inhibitor 1A (p21, Cip1); cyclin-dependent kinase inhibitor 1A variant 1; cyclin-dependent kinase inhibitor 1A variant 2; DNA synthesis inhibitor; MDA6; MDA-6; melanoma differentiation associated protein 6; melanoma differentiation-associated protein; Melanoma differentiation-associated protein 6; OTTHUMP00000016298; p21; p21>WAF1/CIP1>; p21Cip1; p21Cip1/Waf1; p21WAF; PIC1; putative cyclin-dependent kinase inhibitor 1A (p21/WAF1/CIP1); SDI1; SLC12A9; UV96; WAF1; Wild type p53 activated fragment 1 (WAF1); wild-type p53-activated fragment 1 |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.